Global regulatory advancements in biosimilars enhance access to affordable treatments for autoimmune disorders, bone diseases ...

In a recently-issued Director Discretionary Denial decision, U.S. Patent and Trademark Office (USPTO) Acting Director Coke ...

Bayer's steady cash flows from healthcare and crop science products should enable the company to both reduce debt and service current debt levels. However, the high debt levels and slow near-term ...

The 2024 approvals included significant milestones in the biosimilar sector, with the FDA granting approval for the first biosimilar of Stelara, Wezlana and the first denosumab biosimilars, Wyost and ...

Explore the evolving biosimilars landscape with expert insights on development, regulation, and global health harmonization ...

Amgen Inc. (NASDAQ:AMGN) is on the hunt for its next breakthrough drug— a common pursuit among pharmaceutical companies ...

GoodRx reports that in 2025, novel drug and biosimilar approvals lag slightly behind last year, while first generic approvals ...

On July 16, 2025, the District Court for the District of New Jersey entered a Consent Judgment and Injunction in view of a settlement ...

The biologic and biosimilar era has brought about more clinical trials in rheumatology than ever before, and with increasing ...

The drug is indicated for the treatment rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic ...

Biocon Biologics, a subsidiary of Biocon, has introduced Nepexto, a biosimilar to Enbrel, in the Australian market for ...

Biosimilar drugs are drugs that are a lot like biologics, but maybe not identical. Learn why this matters inside.